Olema Pharmaceuticals posts Q3 net loss of $42.2 million on higher R&D spending
Reuters
Nov 10
Olema Pharmaceuticals posts Q3 net loss of $42.2 million on higher R&D spending
Olema Pharmaceuticals Inc. reported a net loss of $42.2 million for the third quarter ended September 30, 2025, compared to a net loss of $34.6 million in the same period in 2024. GAAP research and development expenses increased to $40.0 million from $33.2 million in the prior year quarter, mainly due to higher clinical development-related activities. Non-GAAP research and development expenses were $37.4 million, up from $28.9 million. The company ended the quarter with $329.0 million in cash, cash equivalents, and marketable securities. Key business developments included a new clinical trial agreement with Pfizer to evaluate palazestrant in combination with atirmociclib in ER+/HER2- metastatic breast cancer, initiation of the OPERA-02 Phase 3 trial of palazestrant with ribociclib, and presentation of new data from a Phase 1b/2 study at ESMO 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Olema Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572142-en) on November 10, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.